Literature DB >> 8400288

Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells.

M J Aman1, G Rudolf, J Goldschmitt, W E Aulitzky, C Lam, C Huber, C Peschel.   

Abstract

Interleukin-8 (IL-8) is produced by many cell types upon stimulation with bacterial products or inflammation-associated cytokines such as tumor necrosis factor-alpha and IL-1. Interferons (IFNs) represent another group of cytokines that are induced by similar stimuli in inflammatory reactions. We show now that type-I IFNs are potent inhibitors of IL-8 expression in vitro and in vivo. A significant reduction of both secretion of IL-8 protein and accumulation of IL-8 mRNA in vitro was observed in several cell types comprising peripheral blood mononuclear cells (PBMNC) from healthy donors and from patients with chronic myelogenous leukemia (CML), the myelomonocytic cell line THP-1, and bone marrow (BM) stromal cells as a representative model for BM microenvironment. By contrast, in lipopolysaccharide-stimulated polymorphonuclear phagocytes IFN failed to suppress IL-8 expression. In untreated patients with CML, a constitutive expression of IL-8 mRNA was detected in freshly isolated PBMNC that was markedly reduced 5 hours after therapeutic application of IFN-alpha. The mechanism of IL-8 downregulation was studied more in detail in the THP-1 cell line. The experiments showed that de novo protein synthesis was not required for the inhibitory effect. RNA decay analysis and nuclear run-on assays suggest that in THP-1 cell line the inhibition of IL-8 expression is predominantly regulated at the posttranscriptional level.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8400288

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Association of plasma adiponectin concentrations with chronic lymphocytic leukemia and myeloproliferative diseases.

Authors:  Ferit Avcu; A Ugur Ural; M Ilker Yilmaz; Necati Bingol; Oral Nevruz; Kayser Caglar
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

Review 2.  Progress against cancer.

Authors:  S Broder; J E Karp
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 3.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 4.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

5.  Direct activation of human peritoneal mesothelial cells by heat-killed microorganisms.

Authors:  P Kinnaert; J P De Wilde; B Bournonville; C Husson; I Salmon
Journal:  Ann Surg       Date:  1996-12       Impact factor: 12.969

6.  Molecular and functional characterization of turkey interferon.

Authors:  M Suresh; K Karaca; D Foster; J M Sharma
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

7.  Transcriptional inhibition of the interleukin-8 gene by interferon is mediated by the NF-kappa B site.

Authors:  I C Oliveira; N Mukaida; K Matsushima; J Vilcek
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

Review 8.  Cytokine therapeutics: lessons from interferon alpha.

Authors:  J U Gutterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

Review 9.  Biotherapy of chronic myelogenous leukemia.

Authors:  W E Aulitzky; C Peschel; F Schneller; C Huber
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

10.  Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells.

Authors:  L Schandené; G F Del Prete; E Cogan; P Stordeur; A Crusiaux; B Kennes; S Romagnani; M Goldman
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.